Rheumatoid Arthritis Therapy Reappraisal
Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes...
Furkejuvvon:
| Materiálatiipa: | Online |
|---|---|
| Giella: | eaŋgalasgiella |
| Almmustuhtton: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Fáttát: | |
| Liŋkkat: | ONIX_20210501_9783039430901_843 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
| _version_ | 1869524360461549568 |
|---|---|
| collection | Directory of Open Access Books |
| description | Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA. |
| format | Online |
| id | doab-20.500.12854ir-69097 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-690972024-03-31T13:10:52Z Rheumatoid Arthritis Therapy Reappraisal Müller, Rüdiger rheumatoid arthritis sleep sleep disorders pain osteoporosis fracture fracture risk assessment tool treat-to-target certolizumab pegol csDMARDs glucocorticoids intra-articular injections DAS 28 ACR response HAQ-DI TNFα golimumab efficacy tolerability immunogenicity methotrexate posology titration oral route subcutaneous route bioavailability effectiveness periodontitis periodontal disease anti-citrullinated protein autoantibodies rheumatoid factor smoking medication Porphyromonas gingivalis Rheumatoid arthritis matrix metalloproteinase 3 infliximab pharmacogenomics anti-TNF personalized medicine baricitinib disease-modifying antirheumatic drugs pain perception outcomes research patient perspective Rheumatoid Arthritis therapy DMARD MTX Tumor Necrosis Factor-Alpha Inhibitors ankylosing spondylitis biosimilar switching synovial fibroblasts cytokine osteoclast herbal medicine methylation next-generation sequencing recovery of function fatigue productivity tofacitinib oral Th1.17 IL-17A IFN-γ, CD73 adenosine psoriatic arthritis regulation pseudoerosions hand foot ultrasonography radiography computed tomography magnetic resonance imaging n/a thema EDItEUR::M Medicine and Nursing Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA. 2021-05-01T15:41:03Z 2021-05-01T15:41:03Z 2020 book ONIX_20210501_9783039430901_843 9783039430901 9783039430918 https://directory.doabooks.org/handle/20.500.12854/69097 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/2866 https://mdpi.com/books/pdfview/book/2866 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03943-091-8 10.3390/books978-3-03943-091-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039430901 9783039430918 260 Basel, Switzerland open access |
| spellingShingle | rheumatoid arthritis sleep sleep disorders pain osteoporosis fracture fracture risk assessment tool treat-to-target certolizumab pegol csDMARDs glucocorticoids intra-articular injections DAS 28 ACR response HAQ-DI TNFα golimumab efficacy tolerability immunogenicity methotrexate posology titration oral route subcutaneous route bioavailability effectiveness periodontitis periodontal disease anti-citrullinated protein autoantibodies rheumatoid factor smoking medication Porphyromonas gingivalis Rheumatoid arthritis matrix metalloproteinase 3 infliximab pharmacogenomics anti-TNF personalized medicine baricitinib disease-modifying antirheumatic drugs pain perception outcomes research patient perspective Rheumatoid Arthritis therapy DMARD MTX Tumor Necrosis Factor-Alpha Inhibitors ankylosing spondylitis biosimilar switching synovial fibroblasts cytokine osteoclast herbal medicine methylation next-generation sequencing recovery of function fatigue productivity tofacitinib oral Th1.17 IL-17A IFN-γ, CD73 adenosine psoriatic arthritis regulation pseudoerosions hand foot ultrasonography radiography computed tomography magnetic resonance imaging n/a thema EDItEUR::M Medicine and Nursing Rheumatoid Arthritis Therapy Reappraisal |
| title | Rheumatoid Arthritis Therapy Reappraisal |
| title_full | Rheumatoid Arthritis Therapy Reappraisal |
| title_fullStr | Rheumatoid Arthritis Therapy Reappraisal |
| title_full_unstemmed | Rheumatoid Arthritis Therapy Reappraisal |
| title_short | Rheumatoid Arthritis Therapy Reappraisal |
| title_sort | rheumatoid arthritis therapy reappraisal |
| topic | rheumatoid arthritis sleep sleep disorders pain osteoporosis fracture fracture risk assessment tool treat-to-target certolizumab pegol csDMARDs glucocorticoids intra-articular injections DAS 28 ACR response HAQ-DI TNFα golimumab efficacy tolerability immunogenicity methotrexate posology titration oral route subcutaneous route bioavailability effectiveness periodontitis periodontal disease anti-citrullinated protein autoantibodies rheumatoid factor smoking medication Porphyromonas gingivalis Rheumatoid arthritis matrix metalloproteinase 3 infliximab pharmacogenomics anti-TNF personalized medicine baricitinib disease-modifying antirheumatic drugs pain perception outcomes research patient perspective Rheumatoid Arthritis therapy DMARD MTX Tumor Necrosis Factor-Alpha Inhibitors ankylosing spondylitis biosimilar switching synovial fibroblasts cytokine osteoclast herbal medicine methylation next-generation sequencing recovery of function fatigue productivity tofacitinib oral Th1.17 IL-17A IFN-γ, CD73 adenosine psoriatic arthritis regulation pseudoerosions hand foot ultrasonography radiography computed tomography magnetic resonance imaging n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | rheumatoid arthritis sleep sleep disorders pain osteoporosis fracture fracture risk assessment tool treat-to-target certolizumab pegol csDMARDs glucocorticoids intra-articular injections DAS 28 ACR response HAQ-DI TNFα golimumab efficacy tolerability immunogenicity methotrexate posology titration oral route subcutaneous route bioavailability effectiveness periodontitis periodontal disease anti-citrullinated protein autoantibodies rheumatoid factor smoking medication Porphyromonas gingivalis Rheumatoid arthritis matrix metalloproteinase 3 infliximab pharmacogenomics anti-TNF personalized medicine baricitinib disease-modifying antirheumatic drugs pain perception outcomes research patient perspective Rheumatoid Arthritis therapy DMARD MTX Tumor Necrosis Factor-Alpha Inhibitors ankylosing spondylitis biosimilar switching synovial fibroblasts cytokine osteoclast herbal medicine methylation next-generation sequencing recovery of function fatigue productivity tofacitinib oral Th1.17 IL-17A IFN-γ, CD73 adenosine psoriatic arthritis regulation pseudoerosions hand foot ultrasonography radiography computed tomography magnetic resonance imaging n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20210501_9783039430901_843 |